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Abstract
Background: Whether drug-eluting stents with biodegradable polymers (BP-DES) improve 
safety, especially with respect to stent thrombosis (ST) compared with permanent polymers DES 
(PP-DES), remains uncertain. We aimed to compare the short- and long-term outcomes and 
the ST risk in patients treated with BP-DES vs. PP-DES.
Methods: We searched Medline, Embase, Web of science, CENTRAL databases, and confe-
rence proceedings/abstracts for randomized controlled trials (RCTs) comparing BP-DES with 
PP-DES. The primary endpoint was to compare the risks of overall and different temporal 
categories of definite/probable ST. Other clinical outcomes were target lesion revascularization 
(TLR), myocardial infarction (MI), and all-cause death in short-term (£ 1 year) and long-
-term follow-up. The meta-analyses were performed by computing odds ratios (ORs) with 95% 
confidence intervals (CIs) using a random-effects model.
Results: Nineteen RCTs including 20,229 patients were analyzed. Overall, BP-DES signifi-
cantly decreased the risks of very late definite/probable ST (OR 0.33; 95% CI 0.16–0.70), and 
TLR in long-term follow-up (OR 0.70; 95% CI 0.52–0.95) compared with PP-DES. There 
were no significant differences between the groups regarding MI incidence and mortality du-
ring both short and long follow-up periods. In stratified analyses, the long-term superiority of 
BP-DES was maintained only by using first-generation DES as the comparators.
Conclusions: The present meta-analysis indicated that BP-DES were more efficacious than 
PP-DES at reducing the risks of very late ST and long-term TLR, but it could vary by hetero-
geneities in the use of PP-DES comparators. Additional rigorous RCTs with longer follow-up 
periods are warranted to verify these very promising long-term endpoints. (Cardiol J 2014; 21, 
5: 557–568)
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Introduction
Over the last decade, the introduction of drug-
-eluting stents (DES) has greatly changed the world 
of interventional cardiology [1]. First-generation 
DES with releasing antiproliferative agents from 
permanent polymer coatings have shown better 
performance in reducing the risk of restenosis and 
subsequent revascularization than bare metal stents 
[2], but at the expense of an increased occurrence of 
very late stent thrombosis (ST) [3, 4]. Incomplete 
endothelialization, delayed vessel healing and remo-
deling due to chronic inﬂammation within stented 
segment are likely to cause concerns for the DES 
[5, 6]. The persistence of durable polymer coatings 
on DES might trigger the inﬂammation reaction 
after completed drugs elution [5, 7, 8]. To address 
the problem, different stent coating strategies have 
been developed [9] including biocompatible durable 
polymers, biodegradable polymers DES (BP-DES) 
and polymer-free DES. Second-generation DES are 
coated with a thinner permanent and biocompatible 
ﬂuorocopolymer [1, 9]. Many trials have been con-
ducted to indicate the lower rate of ST in patients 
treated with second-generation DES during long-
-term follow-up [10]. Nevertheless, the ongoing 
minimal inﬂammation process related to durable 
polymer materials is still under observation [11, 12].
Biodegradable polymer coatings on DES are 
regarded as a promising step forward in polymer 
technology [13]. BP-DES could provide a non-
-thrombogenic coating of exposed stent surfaces 
to decrease the risk of late complications [13–18]. 
Prior reports [15, 17] have revealed that biode-
gradation of the polymers within 6–9 months had 
promising long-term clinical results, especially 
regarding very late ST. In the latest SORT OUT V 
trial [19], however, it was found that the incidence 
of ST was 0.7% for biodegradable polymers based 
biolimus-eluting stents (Nobori) and 0.2% for per-
manent polymers sirolimus-eluting Cypher stents 
at both 9 and 12 months (p = 0.034). Because of 
the low rates of ST [1], individual trials comparing 
BP-DES and permanent polymers-DES (PP-DES) 
were not appropriately powered to detect a statisti-
cally signiﬁcant difference in the rates of adverse 
events [20]. We conducted a meta-analysis, which 
increases the statistical reliability by summarizing 
the results from all available trials, to investigate 
the short- and long-term effects and the ST rate of 
BP-DES compared with PP-DES in patients under-
going percutaneous coronary intervention (PCI).
Methods
Selection criteria
Eligibility criteria were: (1) randomized clini-
cal trials (RCTs) comparing BP-DES with PP-DES 
in patients undergoing PCI; (2) studies reporting 
data on the outcomes of interest (reported below). 
Exclusion criteria were: (1) duplicated data; 
(2) sub-study of the RCT; (3) ongoing trials.
Search strategy
Studies were identiﬁed by searching electro-
nic databases including Medline, Embase, Web 
of Science and the Cochrane Central Register 
of Controlled Trials (CENTRAL). This search 
was supplemented by scanning reference lists 
of eligible studies and relevant websites (www.
clinicaltrialresults.org, www.tctmd.com, www.the-
heart.org, www.cardiosource.com, www.escardio.
org). No limits were applied for language, date, or 
publication status. The following keywords and cor-
responding Medical Subject Headings were used: 
“bioresorbable”, “bioabsorbable”, “biodegradable”, 
“drug-eluting stent”, and “drug-coated stent”. The 
last search was run on 8 June 2013.
Study selection and data collection
Two independent investigators (XWN, CLY) 
assessed reports for eligibility at title and/or abs-
tract level, and then extracted data from shortli-
sted studies on pre-speciﬁed forms. Information 
included: (1) the trial’s design, inclusion and 
exclusion criteria; (2) baseline patient and lesion 
characteristics; (3) features of the intervention and 
control arms; (4) clinical outcomes. In an attempt to 
overcome incomplete or selective data reporting, 
manuscripts that were presented at a meeting but 
had not yet been published in full-text form were 
included. As to missing or unclear information, 
we tried to contact original trial researchers by 
telephone or e-mail.
Assessment of risk of bias  
in individual studies
Two investigators independently (XWN, CLY) 
evaluated the internal validity of eligible trials in 
accordance with a set of 7 criteria of the Cochrane 
Handbook [21]: random sequence generation, al-
location concealment, blinding of participants and 
personnel, blinding of outcome assessment, incom-
plete outcome data, selective outcome reporting, 
and other sources of bias (adequate description of 
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sample size calculation and detailed disclosures of 
sources of funding). The judgements of bias were 
expressed as “Low risk”, “High risk” or “Unclear 
risk”. All divergences were resolved by consensus.
Study outcomes and deﬁnitions
The primary endpoints chosen for this meta-
-analysis were the cumulative rates of deﬁnite/probable 
ST as well as the occurrences of early/late (0 days 
to 1 year), very late (> 1 year) deﬁnite/probable ST. 
The secondary endpoints were ischemia-driven target 
lesion revascularization (TLR), myocardial infarction 
(MI), all-cause death. Endpoints occurred within 
1 year follow-up time were deﬁned as the short-term 
outcomes and those beyond 1 year as the long-term. 
Studies reporting only target vascular revasculariza-
tion but not TLR data were excluded in TLR analyses.
The deﬁnitions of deﬁnite/probable ST and 
MI complied with the Academic Research Consor-
tium (ARC) criteria [22]. TLR was deﬁned as any 
percutaneous or surgical revascularization of the 
target lesion owing to symptoms or objective signs 
of ischemia as well as luminal renarrowing ≥ 50% 
detected by angiography at follow-up.
Statistical analysis
Two investigators (DC, YLY) examined data 
from all identiﬁed studies. When 2 or more RCTs 
were available for data pooling, meta-analyses 
were conducted for any outcome according to the 
intention-to-treat principle. Because of rare events 
and imbalance between groups, dichotomous 
outcomes were analyzed by computing pooled odds 
ratios (ORs) with 95% conﬁdence intervals (CIs) 
using the DerSimonian and Laird random-effects 
model [21]. Effect of treatment could not be as-
sessed in trials when no events were reported in 
two arms. For trials in which no event occurred in 
one group, an automatic ‘zero cell’ correction was 
used in such groups [23]. Statistical heterogeneity 
was evaluated by the Cochrane Q test and the I2 
statistic (with p values < 0.1 and I2 values > 50% 
regarded as signiﬁcant inconsistency) [21]. We 
used the funnel plot and Egger’s tests to evaluate 
the presence of publication bias for the endpoints 
[21]. Sensitivity analyses were conducted to assess 
the consistency of primary outcomes, including 
different stent types and dual antiplatelet therapy 
duration (aspirin and thienopyridine). The treat-
ment effects were examined by testing whether 
consecutively deleting each trial would change the 
overall treatment effect of the meta-analysis dra-
matically. All endpoints were evaluated in separate 
subgroup analyses according to the pre-speciﬁed 
stratiﬁed lengths of follow-up time. Results were 
statistically significant at two-sided p < 0.05. 
Statistical computations were performed with 
Review Manager 5.1 (the Cochrane Collaboration, 
Copenhagen, Denmark) and Stata 11.0 (College 
Station, Texas, USA).
Results
Eligible studies
From a total number of 836 potentially relevant 
publications, 19 RCTs with 27 studies met the 
inclusion criteria and were selected. Seventeen of 
these were full-text articles [19, 24–39] and 2 were 
meeting presentation [40, 41]. A ﬂow diagram de-
picting the process of search strategy is shown in 
Figure 1, and main characteristics of the included 
studies are described in Table 1. Among a total 
number of 20,229 patients that were enrolled, 11,134 
were randomized to receive BP-DES, and 9,095 to 
PP-DES. Biodegradable polymer sirolimus-eluting 
stents (SES) was used in 9 trials (3,716 patients) 
and biolimus-eluting stents with a biodegradable 
polymer in 8 trials (6,034 patients). The remaining 
2 trials used respectively everolimus and paclitaxel 
as drugs coated on BP-DES. With regard to the PP-
-DES arm, all the patients from the included studies 
were treated either with first-generation DES, 
SES (4,481 patients) and paclitaxel-eluting stents 
(1,003 patients), or with second-generation DES, 
everolimus-eluting stents (EES) (3,611 patients). 
The mean age of participants in individual trials ran-
ged from 57 to 69 years with the majority of patients 
being male. The percentage of diabetes mellitus 
ranged from 15% to 60%. Patients with acute MI 
were included in 8 trials [19, 25–27, 30, 32, 33, 38]. 
Recommended duration of dual antiplatelet therapy 
was at least 6 months in all trials except for 3 [38, 
40, 41]. Follow-up ranged from 9 to 48 months and 
a weighted mean follow-up was 25.8 months. Some 
additional long-term follow-up information was 
retrieved from web-posted conference proceedings 
[42–44]. In terms of ST, only one trial did not adopt 
the ARC deﬁnition [35].
Table 2 lists the risk of bias among studies 
which were judged by 7 criteria [21]. All but 5 trials 
were described as randomization and allocation 
concealment adequate. Clinical endpoints were 
adjudicated in a blinded manner in 13 trials. All 
trials had a withdrawal of < 10% at the time of pub-
lication of the outcomes of interest in our analysis. 
Two meeting presentations [40, 41] are registered 
with ClinicalTrials.gov, number (NCT00825773, 
NCT00887211), which were not reported in the 
table.
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Meta-analysis
Stent thrombosis. 18 RCTs including 18,529 
patients reported the frequency of ARC deﬁnite or 
probable ST and were used for the quantitative ana-
lysis. Among the studied population, the incidence 
of overall ST was 0.78% (79 of 10,132) in the BP-
-DES and 1.10% (92 of 8,397) in the PP-DES during 
the longest available follow-up period. In terms 
of the pooled risk of ST, no signiﬁcant difference 
could be detected between BP-DES and PP-DES 
(0.80; 0.58–1.10; p for effect = 0.17; I2 = 4%; 
p for heterogeneity = 0.41). A pre-speciﬁed stra-
tified analysis for early/late and very late ST 
was evaluated. The rate of early/late ST was not 
different between two groups (0.73% vs. 0.82%; 
0.92; 0.65–1.31; p for effect = 0.66; I2 = 1%; p for 
heterogeneity = 0.43; Fig. 2). However, regarding 
the risk of very late ST, BP-DES use was associated 
with a nearly 70% reduction when compared with 
PP-DES (0.3% vs. 0.9%; 0.33; 0.16–0.70; p for ef-
fect = 0.003; I2 = 0%; p for heterogeneity = 0.87; 
Fig. 2).
Target lesion revascularization. 17 RCTs 
including 17,890 patients contributed to the ana-
lysis of overall TLR. No signiﬁcant difference re-
garding TLR was found with BP-DES vs. PP-DES 
in short-term follow-up (3.24% vs. 3.80%; 0.93; 
0.73–1.19; p for effect = 0.57; I2 = 31%; p for 
heterogeneity = 0.12; Fig. 3). However, in long-
-term follow-up, BP-DES use was associated with 
a signiﬁcant reduction in the risk of TLR compared 
with PP-DES (8.42% vs. 10.74%; 0.70; 0.52–0.95; 
p for effect = 0.02; I2 = 38%; p for heterogeneity 
= 0.12; Fig. 3).
Figure 1. Flow diagram of the review process according to the PRISMA statement; RCT — randomized controlled trials.
560 www.cardiologyjournal.org
Cardiology Journal 2014, Vol. 21, No. 5
T
ab
le
 1
. M
ai
n 
ch
ar
ac
te
ri
st
ic
s 
o
f i
nc
lu
d
ed
 s
tu
d
ie
s
T
ri
al
s/
fi
rs
t 
 
au
th
o
r
Y
ea
r 
p
ub
lis
he
d
o
r 
p
re
se
nt
ed
N
um
b
er
o
f 
p
at
ie
nt
s
T
yp
e 
o
f 
st
en
t
M
ea
n
ag
e
[y
ea
rs
]
M
en
[%
]
D
ia
b
et
es
m
el
lit
us
[%
]
D
ur
at
io
n
o
f 
D
A
P
T
[m
o
nt
hs
]
M
ax
im
um
fo
llo
w
-u
p
[m
o
nt
hs
]
R
ef
er
en
ce
d
ia
m
et
er
[m
m
]
Le
si
o
n
le
ng
th
[m
m
]
P
ri
m
ar
y 
 
en
d
p
o
in
t
B
P
-D
E
S
P
P
-D
E
S
Li
 e
t a
l. 
[2
7]
20
10
22
8
S
E
S
S
E
S
60
75
26
12
12
3.
0
N
A
M
A
C
E
N
O
Y
A
 I 
[3
1]
20
12
30
0
S
E
S
S
E
S
57
69
21
12
24
2.
9
18
.2
LL
L
N
E
V
O
 R
E
S
-I 
 
[3
7,
 4
5]
20
10
39
4
S
E
S
P
E
S
64
76
19
6
24
2.
6
13
.8
LL
L
Z
ha
ng
 [3
3]
20
13
66
2
S
E
S
S
E
S
67
69
30
12
24
3.
2
26
.9
M
A
C
E
T
A
R
G
E
T
 I 
[3
9]
20
13
45
8
S
E
S
E
E
S
59
68
15
12
12
2.
9
15
.7
LL
L
IS
A
R
-T
E
S
T
-3
  
[2
4,
 4
6]
20
08
40
4
S
E
S
S
E
S
66
79
27
12
24
2.
7
14
.3
LL
L
IS
A
R
-T
E
S
T
-4
  
[1
7,
 2
6]
20
09
2,
60
3
S
E
S
S
E
S
/E
E
S
66
78
28
6
36
2.
8
15
.0
C
D
, M
I, 
T
LR
S
O
R
T
 O
U
T
 V
 [1
9]
20
13
2,
46
8
B
E
S
S
E
S
65
75
15
12
12
3.
3
18
C
D
, M
I, 
 
D
S
T
, T
V
R
N
O
B
O
R
I 1
-p
ha
se
 1
  
[3
4,
 4
2]
20
07
12
0
B
E
S
P
E
S
64
67
48
6
36
2.
8
11
.2
LL
L
N
O
B
O
R
I 1
-p
ha
se
 2
  
[3
6,
 4
2]
20
09
24
3
B
E
S
P
E
S
63
72
22
6
36
2.
7
10
.7
LL
L
S
ep
ar
ha
m
 e
t a
l. 
 
[3
0]
20
11
20
0
B
E
S
E
E
S
61
65
60
12
12
3.
0
N
A
C
D
, M
I, 
T
V
R
N
O
B
O
R
I-J
A
P
A
N
  
[2
8,
 4
3]
20
11
33
5
B
E
S
S
E
S
67
72
39
9
36
2.
8
12
.7
T
V
F
LE
A
D
E
R
S
 [1
5,
 2
5]
20
08
1,
70
7
B
E
S
S
E
S
65
75
24
12
48
2.
7
12
.6
C
D
, M
I, 
T
V
R
C
O
M
P
A
R
E
 II
 [3
2]
20
13
2,
70
7
B
E
S
E
E
S
63
74
22
12
12
2.
9
17
.1
C
D
, M
I, 
T
V
R
N
E
X
T
 [3
8]
20
13
3,
23
5
B
E
S
E
E
S
69
77
46
3
12
2.
6
19
.4
T
LR
, d
ea
th
, M
I
E
V
O
LV
E
  
[2
9,
 4
4,
 4
7]
20
12
29
1
E
E
S
E
E
S
63
73
19
12
12
2.
6
13
.9
C
D
, M
I, 
T
LF
, 
T
V
R
, L
LL
C
O
S
T
A
R
 II
 [3
5]
20
08
1,
67
5
P
E
S
P
E
S
64
72
28
6
9
2.
8
15
.2
M
A
C
E
E
V
O
LU
T
IO
N
 [4
1]
20
12
1,
90
9
S
E
S
S
E
S
N
A
N
A
N
A
12
12
N
A
N
A
T
V
F
P
R
O
B
E
 [4
0]
20
10
29
0
S
E
S
S
E
S
N
A
N
A
16
N
A
12
N
A
N
A
LL
L
B
P
 —
 b
io
d
eg
ra
d
ab
le
 p
o
ly
m
er
; 
P
P
 —
 p
er
m
an
en
t p
o
ly
m
er
; 
B
E
S
 —
 b
io
lim
us
-e
lu
tin
g 
st
en
ts
; 
D
E
S
 —
 d
ru
g-
el
ut
in
g 
st
en
ts
; 
E
E
S
 —
 e
ve
ro
lim
us
-e
lu
tin
g 
st
en
t;
 P
E
S
 —
 p
ac
lit
ax
el
-e
lu
tin
g 
st
en
ts
; 
S
E
S
 —
 s
ir
o
lim
us
-
-e
lu
tin
g 
st
en
ts
; 
C
D
 —
 c
ar
d
ia
c 
d
ea
th
; 
D
A
P
T
 —
 d
ua
l a
nt
ip
la
te
le
t t
he
ra
p
y;
 L
LL
 —
 la
te
 lu
m
en
 lo
ss
; 
M
A
C
E
 —
 m
aj
o
r 
ad
ve
rs
e 
ca
rd
ia
c 
ev
en
ts
; 
M
I —
 m
uo
ca
rd
ia
l i
nf
ar
ct
io
n;
 D
S
T
 —
 d
ef
in
ite
 s
te
nt
 th
ro
m
b
o
si
s;
  
T
V
R
 —
 ta
rg
et
 v
es
se
l r
ev
as
cu
la
ri
sa
tio
n;
 T
V
F 
—
 ta
rg
et
 v
es
se
l f
ai
lu
re
; 
T
LF
 —
 ta
rg
et
 le
si
o
n 
fa
ilu
re
; 
N
A
 —
 n
o
t a
va
ila
b
le
www.cardiologyjournal.org 561
Xiaowei Niu et al., Biodegradable or permanent polymer coronary stents
Myocardial infarction. 18 RCTs including 
19,632 patients contributed to the analysis of 
overall MI. The use of BP-DES vs. PP-DES re-
sulted in similar risks of MI during both short 
follow-up period (2.91% vs. 2.66%; 1.13; 0.95–
–1.35; p for effect = 0.17; I2 = 0%; p for he-
terogeneity = 0.78; Fig. 4) and long follow-up 
period (4.83% vs. 4.91%; 0.98; 0.78–1.23; p for 
effect=0.85; I2 = 0%; p for heterogeneity = 0.81; 
Fig. 4).
All-cause death. All-cause death was repor-
ted in 16 RCTs enrolling 17,723 patients. BP-DES 
and PP-DES use showed similar risks of death in 
both short-term follow-up (2.21% vs. 2.41%; 1.00; 
0.82–1.23; p for effect = 0.98; I2 = 0%; p for hete-
rogeneity = 0.94; Fig. 5) and long-term follow-up 
(6.73% vs. 7.56%; 0.91; 0.75–1.10; p for effect = 
= 0.32; I2 = 0%; p for heterogeneity = 0.65; Fig. 5).
Sensitivity and inﬂuence analysis
Stratiﬁed analyses were performed to evalu-
ate the consistency of our ﬁndings (Table 3A, B). 
The short-term effect of treatment (BP-DES) on 
each endpoint was maintained by using £ 6- or 
12-month duration of dual antiplatelet therapy, 
different DES types. The beneﬁcial long-term tre-
atment effect of BP-DES, however, was supported 
by using ﬁrst-generation DES as the comparators 
and 12-month clopidogrel use. The analyses for the 
BP-DES subtypes (biolimus, sirolimus, paclitaxel 
or everolimus) found: (1) a signiﬁcantly lower risk 
of long-term TLR was associated with the use of 
all types of BP-DES but paclitaxel-eluting stents 
compared with PP-DES; (2) biolimus-eluting stents 
reduced the risk of very late ST in comparison 
with PP-DES.
Because we included 2 RCTs [40, 41] only 
with meeting presentations in the present analysis, 
we repeated all analyses using full-length articles 
alone. The treatment effects for each outcome were 
consistent with our overall ﬁndings. Additionally, 
inﬂuence analysis demonstrated that no single 
study obviously changed the pooled ORs for ST, 
TLR, MI, or death.
Publication bias
Visual inspection of the funnel plot for ST did 
not reveal an apparent asymmetry (Fig. 6) with 
the support of the Egger’s test (p = 0.25). Similar 
results were found for TLR (Egger’s test p = 0.20), 
MI (Egger’s test p = 0.29), and all-cause death 
(Egger’s test p = 0.64).
Table 2. Risk of bias table for included studies.
Study Random  
sequence  
generation
Allocation 
concealment
Blinding of 
participants 
and  
personnel
Blinding  
of outcome 
assessment
Incomplete 
outcome 
data
Selective 
reporting
Other  
bias
Li et al. A B B B A A B
NOYA I B B A A A A A
Zhang et al. A A B B A A A
NEVO RES-I A A A A A A A
TARGET I A A C A A A A
ISAR-TEST-3 A A A A A A A
ISAR-TEST-4 A A B A A A A
SORT OUT V A A B A A A A
NOBORI 1-phase 1 A A B A A A A
NOBORI 1-phase 2 A A B A A A A
Separham et al. B B B B B A B
NOBORI-JAPAN B B B A A A A
LEADERS A A A A A A A
COMPARE II A A C A A A A
NEXT A A B A A A A
EVOLVE A B A A A A A
COSTAR II A A A A A A A
A — low risk; B — unclear risk; C — high risk
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Figure 2. Forest plot for stent thrombosis (ST) in patients treated with biodegradable polymer drug-eluting stents (BP-
-DES) vs. permanent polymer drug-eluting stents (PP-DES) according to prespecified subgroup analyses: (1) early ST/ 
/late ST; (2) very late ST. BP-DES use was associated with a reduction in the risk of very late ST when compared with 
PP-DES; M-H — Mantel-Haenszel; CI — confidence interval.
Figure 3. Forest plot with odds ratios for target lesion revascularization (TLR) associated with biodegradable polymer 
drug-eluting stents (BP-DES) vs. permanent polymer drug-eluting stents (PP-DES) in short- and long-term follow-up. 
BP-DES use was associated with a reduction in the risk of TLR in long-term follow-up when compared with PP-DES; 
M-H — Mantel-Haenszel; CI — confidence interval.
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Figure 4. Forest plot with odds ratios for myocardial infarction (MI) associated with biodegradable polymer drug-
-eluting stents (BP-DES) vs. permanent polymer drug-eluting stents (PP-DES) in short- and long-term follow-up. The 
use of BP-DES vs. PP-DES resulted in similar risks of MI during both short and long follow-up period; M-H — Mantel-
-Haenszel; CI — confidence interval.
Figure 5. Forest plot with odds ratios for death associated with biodegradable polymer drug-eluting stents (BP-DES) 
vs. permanent polymer drug-eluting stents (PP-DES) in short- and long-term follow-up. The use of BP-DES vs. PP-
-DES resulted in similar risks of all-cause death during both short and long follow-up period; M-H — Mantel-Haenszel; 
CI — confidence interval.
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Discussion
Overall ﬁndings
In this meta-analysis with 20,229 patients en-
rolled in 19 randomized trials, main ﬁndings could 
be summarized as follows: (1) BP-DES were asso-
ciated with decreased risks of deﬁnite or probable 
very late ST and long-term TLR compared with 
PP-DES, however, the long-term superiority of BP-
-DES was only maintained by using ﬁrst-generation 
DES as the comparators in stratiﬁed analyses. 
(2) BP-DES had similar rates of deﬁnite or probable 
ST and TLR to PP-DES during the short follow-
-up period. (3) No signiﬁcant difference was found 
regarding efﬁcacy and safety between BP-DES and 
current standard second-generation DES using 
biocompatible permanent polymer. (4) Both groups 
had the comparable rates of MI and all-cause death 
in the short- and long-term follow-up.
Possible mechanisms of beneﬁt
Although differences in DES system per-
formances may be attributed to any of its 3 com-
ponents, namely a metallic stent platform, an 
antiproliferative agent, and a coating polymer [1], 
some changes in coating strategies may account 
Table 3. Stratified analyses of included studies.
A. Odds ratios with 95% confidence intervals for stent thrombosis
Treatment Control Stent thrombosis (ST)
Early/late ST Very late ST Overall ST
BP-DES PP-PES 0.18 (0.02–1.60) 0.18 (0.02–0.96)* 0.10 (0.01–0.83)*
BP-DES PP-SES 0.96 (0.65–1.43) 0.36 (0.17–0.79)* 0.81 (0.58–1.12)
BP-SES PP-DES 0.51 (0.20–1.29) 0.33 (0.05–2.08) 0.74 (0.46–1.19)
BP-BES PP-DES 1.05 (0.62–1.77) 0.33 (0.15–0.75)* 0.90 (0.43–1.87)
BP-EES PP-DES NA NA NA
BP-PES PP-PES NA NA NA
BP-DES PP-DES 0.92 (0.65–1.31) 0.33 (0.16–0.70)* 0.80 (0.58–1.10)
BP-DES 1st generation DES 0.91 (0.61–1.36) 0.28 (0.13–0.62)* 0.77 (0.55–1.09)
BP-DES 2nd generation DES 0.82 (0.46–1.47) 1.00 (0.14–7.14) 0.83 (0.48–1.43)
BP-DES PP-DES (DAPT ≤ 6 months) 0.79 (0.18–3.48) 0.44 (0.05–3.81) 0.58 (0.14–2.38)
BP-DES PP-DES (DAPT 12 months) 1.01 (0.67–1.52) 0.30 (0.13–0.68)* 0.83 (0.59–1.17)
B. Other clinical outcomes
Treatment Control TLR MI All-cause death
Short term Long term Short term Long term Short term Long term
BP-DES PP-PES 0.12  
(0.01–1.14)
0.41  
(0.19–0.89)*
1.05  
(0.64–1.72)
0.62  
(0.30–1.26)
0.49  
(0.19–1.24)
0.70  
(0.30–1.61)
BP-DES PP-SES 0.99  
(0.71–1.39)
0.79  
(0.63–0.99)*
1.18  
(0.92–1.51)
1.02  
(0.80–1.29)
1.01  
(0.78–1.30)
0.91  
(0.74–1.11)
BP-SES PP-DES 0.83  
(0.50–1.37)
0.64  
(0.40–1.00)*
0.69  
(0.36–1.30)
1.12  
(0.54–2.31)
0.66  
(0.28–1.57)
0.73  
(0.41–1.30)
BP-BES PP-DES 1.00  
(0.77–1.30)
0.77  
(0.59–1.00)*
1.15  
(0.94–1.39)
0.95  
(0.75–1.21)
1.03  
(0.84–1.28)
0.92  
(0.76–1.13)
BP-EES PP-DES 0.19  
(0.04–1.02)
0.16  
(0.03–0.81)*
6.83  
(0.38–122.49)
6.83  
(0.38–122.49)
2.57  
(0.12–54.09)
7.92  
(0.45–140.16)
BP-PES PP-PES NA NA 1.49  
(0.82–2.72)
NA 0.69  
(0.20–2.40)
NA
BP-DES PP-DES 0.93  
(0.73–1.19)
0.70  
(0.52–0.95)*
1.13  
(0.95–1.35)
0.98  
(0.78–1.23)
1.00  
(0.82–1.23)
0.91  
(0.75–1.10)
BP-DES 1st generation  
DES
0.91  
(0.65–1.26)
0.77  
(0.64–0.93)*
1.16  
(0.93–1.45)
0.97  
(0.77–1.21)
0.97  
(0.76–1.23)
0.90  
(0.74–1.09)
BP-DES 2nd generation  
DES
0.96  
(0.77–1.19)
0.50  
(0.08–3.23)
1.07  
(0.84–1.35)
1.53  
(0.35–6.65)
1.04  
(0.80–1.34)
1.67  
(0.26–10.63)
BP-DES PP-DES  
(DAPT ≤ 6 months)
0.83  
(0.55–1.28)
0.59  
(0.25–1.41)
1.10  
(0.86–1.39)
0.93  
(0.59–1.47)
0.97  
(0.74–1.28)
0.95  
(0.73–1.22)
BP-DES PP-DES  
(DAPT 12 months)
0.97  
(0.69–1.38)
0.68  
(0.51–0.92)*
1.18  
(0.91–1.55)
0.98  
(0.73–1.33)
1.04  
(0.76–1.42)
0.87  
(0.66–1.15)
*Significant comparisons; The pooled estimates are reported as odds ratio (95% confidence interval); BP — biodegradable polymer;  
PP — permanent polymer; BES — biolimus-eluting stents; DES — drug-eluting stents; EES — everolimus-eluting stent; PES —paclitaxel-
-eluting stents; SES — sirolimus-eluting stents; DAPT — dual antiplatelet therapy; NA — not applicable
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cumulative 1-year ST, and very late ST compared 
with other DES (paclitaxel-, sirolimus-, and zota-
rolimus-eluting stents). Based on these excellent 
outcomes, it will be difﬁcult to see any signiﬁcant 
differences between BP-DES and EES. In a registry 
[48] including 814 patients with a median follow-up 
of 22 months, biolimus-eluting stents were similar 
to EES regarding safety (ST, MI or death) or efﬁcacy 
(target vessel revascularization). In future clinical 
trials, more second-generation DES should be con-
sidered competitive comparators to corroborate the 
present ﬁnding.
Additionally, when the clinical follow-up period 
was extended (> 1 year), the improvement in cli-
nical restenosis (TLR) was maintained in patients 
treated with BP-DES. This ﬁnding was potentially 
associated with the reduction of the inﬂammation 
burden and late catch-up restenosis after implanta-
tion of BP-DES [15]. Taken together, both minimi-
zation of the risk of very late ST and the long-term 
potent anti-restenosis effects in part reﬂected the 
accelerated re-endothelialization and improved 
coronary artery healing with BP-DES use.
DES comparisons
Although the results of our stratiﬁed analysis 
showed a consistent short-term effect of treatment 
among different BP-DES types, we did detect dif-
ferences in the rates of very late ST and long-term 
TLR. The potential clinical beneﬁt of BP-DES was 
thought to fully grow only during the late phase 
after stent intervention, when the polymer coatings 
already degraded and antiproliferative dugs com-
pletely eluted leaving the stent surface more close 
to bare-metal scaffolds. Therefore, the inﬂuence 
of the polymers and active drugs composing DES 
on long-term clinical outcomes seemed negligible, 
while bare-metal scaffolds may be dominant factors 
of long-term effects [13, 15, 33, 50]. In fact, me-
aningful differences regarding ST in head-to-head 
trials of bare-metal stents have not been reported 
[50]. In theory, the property of BP-DES might al-
low shorter duration of dual antiplatelet therapy. 
However, the beneﬁcial long-term treatment effect 
of BP-DES was only maintained by using 12-month 
duration of dual antiplatelet therapy regimens. This 
might be due to the fact that the complete degra-
dation of most used polymers needed nearly a year 
[15]. The selection of short-term dual antiplatelet 
therapy would need to be reconsidered in patients 
treated with BP-DES. Finally, the estimates varia-
tion was due in part to the subdivision of data into 
several smaller subgroups [51].
Figure 6. Funnel plot comparing standard error (SE) and 
odds ratio (OR) for stent thrombosis.
for these results. Based on lots of animal experi-
ments and studies in DES-treated human subjects, 
researchers have demonstrated that very late ST 
may be caused by incomplete re-endothelialization, 
delayed arterial healing and remodeling due to the 
ongoing stented vessel wall inﬂammation [5, 6]. 
The etiology of the chronic inﬂammatory response 
is multifactorial such as lesion characteristics and 
patient-, device-, and procedural-related factors, 
however, the persistence of permanent polymer 
coatings which eluted antiproliferative drugs was 
likely a primary inﬂammatory stimulus [5, 7, 8]. 
Development of biodegradable polymers on DES 
meant that the stent would be polymer-free and 
drug-free like a bare-metal stent after polymer 
absorption, thereby eliminating the long-term se-
quelae of durable polymer residue [13, 15, 16]. An 
optical coherence tomography study [18] showed 
earlier endothelialization associated with BP-DES 
vs. PP-DES within 9 months after implantation, 
indicating an improved vascular chronic inﬂamma-
tion. Hamilos et al. [14] also found better preserved 
endothelium-dependent vasomotion of BP-DES 
than that of permanent polymer-coated SES. 
Besides biodegradable polymers on DES, the 
biocompatible ﬂuoropolymers used in the second-
-generation DES were associated with less thrombo-
genicity [10]. Although BP-DES offered a theoretical 
advantage over DES with durable biocompatible 
polymers [11, 12, 32, 48], our study failed to de-
monstrate this beneﬁt. This ﬁnding implied that 
the variability in BP-DES efﬁcacy and safety across 
control DES reﬂected a real attenuation of treatment 
effects. Two recent large meta-analyses [10, 49] 
have clearly demonstrated that second-generation 
SES reduced the relative risk of early ST, late ST, 
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Implications of the present study
Firstly, very late ST, which is a rare event but 
more prevalent in higher-risk patients and lesions, 
turned into catastrophic outcomes after 1-year of 
stents’ implantation [22]. In this setting, our meta-
-analysis had the clinical importance, which reve-
aled a performance difference for very late deﬁnite 
or probable ST between BP-DES and PP-DES 
use. Secondly, BP-DES have combined the low 
restenosis rate with the enhanced long-term safety 
proﬁle. It also supported the earlier evidence that 
the presence of residual durable polymers in DES 
initiated a persisting inﬂammatory reaction, which 
not only promoted thrombogenity of the device but 
also potentially increased neointimal hyperplasia 
within the stented segment [5, 7, 8]. Moreover, the 
beneﬁt of BP-DES was at least non-inferior to EES, 
which were regarded as a gold standard to which 
new stent designs should be compared [32]. The 
ﬁnding provided a justiﬁcation for trials further 
evaluating safety of the biodegradable polymer 
stent design in the long-term follow-up.
Limitations of the study
We cannot deny that our study has several 
limitations. Firstly, as this meta-analysis is not 
based on patient-level data, it shares the possible 
shortcomings of the original articles. Moreover, we 
could not conduct subset analyses of patients with 
diabetics, complex lesions, or MI. Secondly, we 
are unable to extend our ﬁndings to other second-
-generation DES (zotarolimus-eluting stents). 
Thirdly, the long-term superiority of BP-DES is 
only against ﬁrst-generation DES, which are not 
used in daily clinical practice. Finally, the selection 
criteria for DES with different coating strategies 
should have a comprehensive assessment of the 
overall devices performance rather than taking 
into consideration only thrombosis susceptibility. 
Notwithstanding these limitations, studies using 
the uniform and standardized deﬁnition of ST 
were included in the meta-analysis to decrease 
the risk of bias. As only RCTs were included, our 
point estimates for all outcomes were less likely 
inﬂuenced by confounding bias.
Conclusions
The present meta-analysis showed that BP-
-DES were more efﬁcacious than PP-DES at redu-
cing the risks of very late deﬁnite/probable ST and 
long-term TLR, but it could vary by heterogeneities 
in the use of PP-DES comparators. No signiﬁcant 
differences regarding safety and efﬁcacy outcomes 
within short follow-up period were observed. RCTs 
with longer follow-up are warranted to verify these 
very promising long-term endpoints.
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